# Imara

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imara-2

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.imaratx.com
- Total disclosed funding: $75M
- Latest round: Series B (Mar 18, 2019)
- Investors on record: 9

## About

Founded in 2016 and based in Massachusetts, US, Imara, Inc. is a biopharmaceutical company that develops novel therapeutics to treat patients suffering from rare cell diseases. The company develops IMR-687, a highly selective and potent small-molecule inhibitor that helps in reducing the red blood cell sickling and blockage of blood vessels.

## Funding rounds

- Series B, Mar 18, 2019, $44M — New Enterprise Associates, OrbiMed Advisors, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments, RA Capital Management, Rock Springs Capital, Arix Bioscience
- Series A, Apr 14, 2016, $31M — New Enterprise Associates, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B